Showing 653 results

Filters Content type: News, Editors' picks Topic: New & experimental hepatitis C treatment

News and information about clinical trials and regulatory approval of new medications to treat hepatitis C.

Hepatitis C treatment

Sofosbuvir & ribavirin cures 75% of genotype 1 HIV/HCV co-infected patients

News
5 March 2014
Hepatitis C treatment

AbbVie '3D' combination cures 99% of genotype 1b hepatitis C

News
5 March 2014
New & experimental hepatitis C treatment

Simeprevir cures almost 80% of first-time co-infected hepatitis C patients

News
5 March 2014
Hepatitis C treatment

Faldaprevir plus interferon and ribavirin cures hepatitis C in most people with HIV/HCV co-infection

News
5 March 2014
Hepatitis C treatment

Six-week oral treatment can cure hard-to-treat hepatitis C patients

News
4 March 2014
Access to healthcare

Pharma refuses to ensure access to lifesaving hepatitis C treatment at global meeting

Editor's pick
Treatment Action Group
28 February 2014
New & experimental hepatitis C treatment

European Medicines Agency advises on compassionate use of a new combination therapy for chronic hepatitis C

Editor's pick
European Medicines Agency
21 February 2014
Access to healthcare

Fighting For Global Access to Hepatitis C Therapies

Editor's pick
HepMag
19 February 2014
Hepatitis C treatment

Treating HCV -- Is the Price Right?

Editor's pick
Med Page Today
19 February 2014
New & experimental hepatitis C treatment

The deadly toll of drug-approval drag

Editor's pick
Winnipeg Free Press
14 February 2014
New & experimental hepatitis C treatment

Gilead's CEO Says New Hepatitis C Drug Attracts Payers

Editor's pick
Bloomberg Businessweek
13 February 2014
New & experimental hepatitis C treatment

Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Hepatitis C

Editor's pick
Gilead press release
11 February 2014
New & experimental hepatitis C treatment

New hepatitis C pill lifts Gilead's 4Q sales

Editor's pick
Bloomberg Businessweek
7 February 2014
New & experimental hepatitis C treatment

Gilead to license hepatitis C drug to lower-cost manufacturers in India

Editor's pick
Reuters
6 February 2014
New & experimental hepatitis C treatment

Gilead, local generic players in talks to bring hepatitis C drug into India

Editor's pick
The Hindu
4 February 2014
New & experimental hepatitis C treatment

Abbvie Strong Hep C Drug Data and the Looming Battle With Gilead Sciences

Editor's pick
The Street
3 February 2014
New & experimental hepatitis C treatment

AbbVie Completes Largest Phase III Program of an All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C Genotype 1

Editor's pick
AbbVie press release
31 January 2014
Hepatitis C treatment

US medical societies launch new hepatitis C treatment guidelines

News
30 January 2014
Access to healthcare

At $84000 Gilead Hepatitis C Drug Sets Off Payer Revolt

Editor's pick
Bloomberg
27 January 2014
New & experimental hepatitis C treatment

Only just the beginning of the end of hepatitis C

Editor's pick
The Lancet (editorial)
26 January 2014
New & experimental hepatitis C treatment

Hep C drug deleobuvir pulled from clinical study, citing high rate of early discontinuations

Editor's pick
Project Inform
21 January 2014
New & experimental hepatitis C treatment

European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection

Editor's pick
Gilead press release
17 January 2014
New & experimental hepatitis C treatment

Bristol-Myers Ties Hepatitis C Success to Gilead’s Pill

Editor's pick
Bloomberg
14 January 2014
New & experimental hepatitis C treatment

What Is a Hepatitis C Drug Worth?

Editor's pick
Roll Call
14 January 2014